+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Macular Edema - Pipeline Review, H1 2015

  • ID: 3280636
  • Report
  • May 2015
  • 72 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Promedior, Inc.
  • MORE
Macular Edema - Pipeline Review, H1 2015

Summary

This, ‘Macular Edema - Pipeline Review, H1 2015’, provides an overview of the Macular Edema’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Macular Edema
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Macular Edema
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Promedior, Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Macular Edema Overview
Therapeutics Development
Pipeline Products for Macular Edema - Overview
Pipeline Products for Macular Edema - Comparative Analysis
Macular Edema - Therapeutics under Development by Companies
Macular Edema - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Macular Edema - Products under Development by Companies
Macular Edema - Companies Involved in Therapeutics Development
Allergan, Inc.
Clearside BioMedical, Inc.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Promedior, Inc.
Regeneron Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(triamcinolone acetonide + aflibercept) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aflibercept (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
beclomethasone dipropionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
triamcinolone acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macular Edema - Recent Pipeline Updates
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion
Jan 23, 2015: EYLEA(aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC’s Ophthalmology Drug Phase I/II trial
Oct 06, 2014: EYLEA (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)
Sep 04, 2014: Regeneron Announces Submission of Application for EYLEA (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion
Feb 25, 2014: NICE gives green light to treatment for macular oedema in final guidance
Feb 24, 2014: Regeneron Announces FDA Acceptance of EYLEA (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
Dec 27, 2013: NICE gives green light to treatment for macular oedema in final draft guidance
Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug
Nov 22, 2013: EYLEA Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Macular Edema, H1 2015
Number of Products under Development for Macular Edema - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Macular Edema - Pipeline by Allergan, Inc., H1 2015
Macular Edema - Pipeline by Clearside BioMedical, Inc., H1 2015
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Macular Edema - Pipeline by Pfizer Inc., H1 2015
Macular Edema - Pipeline by Promedior, Inc., H1 2015
Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Macular Edema Therapeutics - Recent Pipeline Updates, H1 2015
Macular Edema - Dormant Projects, H1 2015
Macular Edema - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Macular Edema, H1 2015
Number of Products under Development for Macular Edema - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
- Allergan, Inc.
- Clearside BioMedical, Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Promedior, Inc.
- Regeneron Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll